ClinicalTrials.gg
RecruitingNCT06372717Updated Oct 28, 2026

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

A Phase 1 interventional study of APL-4098 and Azacitidine and APL-4098 in Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia and Myelodysplastic Syndrome With Excess Blasts, sponsored by Apollo Therapeutics Ltd. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Apollo Therapeutics Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Oct 28, 2026Site recruiting status changedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, Phase 1 study to determine the safety, tolerability, and efficacy of APL-4098 alone, and in combination with azacitidine, and in combination with azacitidine plus venetoclax for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)/AML and MDS-excess blasts (EB).

02

Conditions studied

  • Acute Myeloid Leukemia Refractory
  • Myelodysplastic Syndrome Acute Myeloid Leukemia
  • Myelodysplastic Syndrome With Excess Blasts
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia (AML)
  • Newly Diagnosed Acute Myeloid Leukemia (AML)
03

In context

Anemia, Refractory, with Excess of Blasts

65 studies on the registry are indexed under Anemia, Refractory, with Excess of Blasts; 6 are open to participants now.

This study's planned enrollment of 100 is above the median of 37 across 62 interventional studies indexed under Anemia, Refractory, with Excess of Blasts.

Browse Anemia, Refractory, with Excess of Blasts studies →

Lead sponsor

Apollo Therapeutics Ltd is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Confirmed diagnosis of acute myeloid leukemia (R/R AML), myelodysplastic syndrome (MDS)/ AML, or MDS-excess blasts (MDS-EB) with the following characteristics: R/R AML (primary or secondary, including treatment-related), participant is intolerant to, or considered ineligible for available therapies known to provide clinical benefit; Newly diagnosed (ND AML), previously untreated, and considered unfit for available front line therapies or standard intensive chemotherapy.
  • WBC count ≤ 25,000/microliter
  • Performance Status of ≤ 2
  • Weight ≥ 40kg
  • Female participants of must have negative serum pregnancy test at screening; must not plan to become pregnant or have ova harvested or breastfeed while on study; must be willing to use specific or avoid intercourse
  • Male participants must be willing to use specific contraception and not plan to impregnant a female partner or donate sperm while on study
  • Participant must be willing and able to provide written and to comply with the requirements of the trial

Exclusion criteria

Exclusion Criteria:

  • Certain prior therapies such as: received an stem cell transplant within 6 months of screening, received an autologous stem cell transplant within 3 months of screening, received any anti-cancer treatments within 2 weeks of Cycle 1 Day 1, prior radiation therapy within 4 weeks of screening
  • Certain medical conditions such as: other , myocardial infarction within 6 months of screening, symptomatic congestive heart failure, uncontrolled active infection, history of arterial thrombosis within 6 months of screening
  • Diagnostic assessments: \< 45%, Fridericia's interval > 470msec, and/or alanine aminotransferase > 3 x (ULN), total > 1.5 x ULN, calculated or measured \< 45 mL/minute (multiply by 0.85 if female)
  • Infectious disease: positive, active and/or C
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Phase: APL-4098 monotherapy

    Dose escalation with different dosing levels of APL-4098.

    Drug: APL-4098

  • Experimental
    Dose Escalation Phase: APL-4098 and azacitidine

    Dose escalation with different dosing levels of APL-4098 in combination with azacitidine.

    Drug: Azacitidine and APL-4098

  • Experimental
    APL-4098 and azacitidine and venetoclax

    Dose escalation with different dosing levels of APL-4098 in combination with azacitidine and venetoclax.

    Drug: Azacitidine and Venetoclax and APL-4098

Interventions

  • DrugAPL-4098

    APL-4098 is administered orally in 28-day cycles

  • DrugAzacitidine and APL-4098

    Drug page: AzacitidineStudies of AzacitidineAzacitidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Azacitidine is administered at the standard dose on Day 1 - Day 7 of each 28-day cycle; APL-4098 is administered orally.

  • DrugAzacitidine and Venetoclax and APL-4098

    Drug pages: AzacitidineStudies of AzacitidineAzacitidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · VenetoclaxStudies of VenetoclaxVenetoclax pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Azacitidine is administered at the standard dose on Day 1 - Day 7 of each 28-day cycle; Venetoclax is administered orally; APL-4098 is administered orally.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events [Safety]

    Evaluation of safety parameters including treatment emergent adverse events as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, Electrocardiogram results

    Time frame: Through study completion, approximately one year

  2. Incidence of Dose Limiting Toxicities [Tolerability]

    Evaluation of tolerability parameters including dose limiting toxicities as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, and Electrocardiogram results

    Time frame: Cycle 1 Day 1 to Cycle 2 Day 1 (a cycle is 28 days)

  3. Determine Recommended Phase 2 Dose (RP2D)/Recommended dose range (RDR) levels of APL-4098 alone, in combination with azacitidine, and in combination with azacitidine plus venetoclax.

    Time frame: Approximately one year

  4. Assess the Pharmacokinetics of APL-4098

    Evaluate PK parameters: Maximum plasma concentration (Cmax)

    Time frame: On Days 1, 2, 8, and 15 of Cycle 1, and on Day 1 of Cycle 2 (each cycle is 28 days)

  5. Assess the Pharmacokinetics of APL-4098

    Evaluate PK parameters: area under the curve (AUC)

    Time frame: On Days 1, 2, 8, and 15 of Cycle 1, and on Day 1 of Cycle 2 (each cycle is 28 days)

  6. Assess the Pharmacokinetics of APL-4098

    Evaluate PK parameters: Time to peak concentration (Tmax)

    Time frame: On Days 1, 2, 8, and 15 of Cycle 1, and on Day 1 of Cycle 2 (each cycle is 28 days)

Secondary outcomes

  1. Assess response to disease with APL-4098 alone, in combination with azacitidine, and in combination with azacitidine plus venetoclax.

    R/R AML and MDS/AML participants: response is assessed per European LeukemiaNet (ELN) 2022 criteria MDS-EB participants: response is assessed per revised International Working Group 2023 response criteria

    Time frame: Response is assessed at Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 7 Day 1 (each cycle is 28 days long), then every three cycles thereafter (assessed for up to 2 years)

07

Study locations

8 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2024 (actual). Primary completion is estimated for Jul 2027, 37 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Mar 2027 → Jul 2027 and completion May 2027 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2024
First posted
Apr 18, 2024
StartActual
Jun 4, 2024
Primary completionEst.
Jul 2027was Mar 2027
CompletionEst.
Aug 2027was May 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Hollywood Private Hospital is now Terminated
Oct 28, 2026
Primary completion
Mar 1, 2027→Jul 2027
Oct 28, 2026
Study completion
May 1, 2027→Aug 2027
Oct 28, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedConfirmed diagnosis of relapsed refractory acute myeloid leukemia (R/R AML), myelodysplastic syndrome (MDS)/ AML, or MDS-excess blasts (MDS-EB) with the following characteristics: - R/R AML (primary or secondary, including treatment-related), participant is intolerant to, or considered ineligible for available therapies known to provide clinical benefit; Newly diagnosed (ND AML), previously untreated, and considered unfit for available front line therapies or standard intensive chemotherapy.
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Hollywood Private Hospital is now Terminated
    Primary completion Mar 1, 2027→Jul 2027
    Study completion May 1, 2027→Aug 2027
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedConfirmed diagnosis of relapsed refractory acute myeloid leukemia (R/R AML), myelodysplastic syndrome (MDS)/ AML, or MDS-excess blasts (MDS-EB) with the following characteristics: - R/R AML (primary or secondary, including treatment-related), participant is intolerant to, or considered ineligible for available therapies known to provide clinical benefit; Newly diagnosed (ND AML), previously untreated, and considered unfit for available front line therapies or standard intensive chemotherapy.
    + 2 other changes: verification date and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06372717
Lead sponsor
Apollo Therapeutics Ltd
Responsible party
Sponsor
First posted
Apr 18, 2024
Start date
Jun 4, 2024
Primary completion
Jul 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Apollo Therapeutics
Contact
AP30@apollotx.com
781-479-2267
Sanjay Aggarwal, MD
study chair · Apollo Therapeutics

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azacitidine · Venetoclax

Start the discussion